Abstract Details

Title The Burden of Primary Headache Disorders in Saudi Arabia

Topic Headache

Presentation(s) P03 - (-)

Poster/Presentation
Number 112

Objective

Background BACKGROUND: This was a project within the Global Campaign against Headache. The epidemiology of migraine is well studied in western countries; of tension-type headache (TTH) less so. Very little population-based information is available on either disorder from Eastern Mediterranean region.

Design/Methods DESIGN/METHODS: Country-wide population-based cross-sectional survey of the Arabic-speaking adult population (18-65 years). Interviewers were trained surveyors. Access was by mobile phone, with sampling by random-digit dialing. Diagnoses were made algorithmically: the Arabic translation of a previously-developed questionnaire was validated in a sub-sample re-interviewed by a neurologist. Further questions enquired into disability burden.

Results RESULTS: Among 2,421 respondents (male 62%, female 38%; mean age 32.2 ±12 years), the observed 1-year prevalence of all headache was 63%, of migraine 32%, of TTH 27% and of medication-overuse headache (MOH) 2.7%. Odds ratio of migraine, TTH, and MOD for Female compared to Male were (OR = 1.9), (OR = 0.7) and (OR =3.4), respectively. Mean headache-attributed lost work-days per person/year was 24.0 days for migraine, 6.6 days for TTH and 53.4 days for MOH. Estimated total headache-attributed lost work-days /year in the Saudi population were 99,571,330 days (4% of all working days).

Conclusions CONCLUSIONS: Headache disorders, especially migraine, are highly prevalent in Saudi Arabia; enquiry into possible causes is called for. MOH is also prevalent. Unmet health-care need is evident. The lost-productivity burden is substantial. Effective treatments for headache do not appear to be reaching most of the population.

Authors/Disclosures
PRESENTER	No disclosure on file
Ali M. Al Khathaami, MD (National Guard Health Affair)	No disclosure on file
Suleiman Kojan, MD, FAAN (Flint Neurological Center)	No disclosure on file
	No disclosure on file
	No disclosure on file
Timothy A. Steiner	No disclosure on file
	No disclosure on file
Benjamin M. Greenberg, MD, FAAN (UT Southwestern Medical Center)	Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Clene. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Greenberg has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Siegel Rare Neuroimmune Association. Dr. Greenberg has or had stock in GenrAb.Dr. Greenberg has or had stock in Clene.Dr. Greenberg has received intellectual property interests from a discovery or technology relating to health care. Dr. Greenberg has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��